Schizophrenia Clinical Trials 2024

Schizophrenia Clinical Trials 2024

Schizophrenia research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in schizophrenia clinical trials today.

Schizophrenia Clinical Trials

Here are the 6 most popular medical studies for schizophrenia

Popular filter options for schizophrenia trials

Schizoaffective Disorder Clinical Trials

View 97 Schizoaffective Disorder medical studies.

Schizophreniform Disorder Clinical Trials

View 70 Schizophreniform Disorder medical studies.

Schizophrenia Clinical Trials With No Placebo

View 98 schizophrenia medical studies that do not have a placebo group.

View More Schizophrenia Trials

See another 76 medical studies focused on schizophrenia.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to schizophrenia

What are the top hospitals conducting schizophrenia research?

When it comes to advancing the understanding and treatment of schizophrenia, several top hospitals are leading the way with their groundbreaking clinical trials. In Toronto, the Centre for Addiction and Mental health is at the forefront with five active trials focused on this complex condition. With a remarkable history of 48 completed studies since their first recorded schizophrenia trial in 1999, this institution has been dedicated to making strides in mental health research. Meanwhile, over in Atlanta, the Atlanta Center for Medical Research is actively conducting four trials targeting schizophrenia. Their commitment to advancing knowledge about this disorder can be traced back to their initial trial in 2002.

In DeSoto, Texas, the Neurocrine Clinical Site has recently emerged as an important player in addressing schizophrenia through clinical trials. Although they have only conducted four trials thus far since recording their first one in 2021, their dedication holds great promise for future breakthroughs.

Heading across international borders to Berlin brings us to Hassman Research Institute. This esteemed hospital boasts four ongoing clinical trials exploring various aspects of schizophrenia while having achieved significant progress through twenty-seven previous investigations since starting their pioneering work in 2015.

Last but not least, we turn our attention to Pittsburgh's University of Pittsburgh where three active clinical trials are currently underway focusing on unraveling the mysteries surrounding schizophrenia. Since initiating research efforts back in 2001 with their very first recorded trial on this subject matter; they have completed eleven additional studies that have contributed valuable insights into this condition.

These prominent hospitals serve as beacons of hope for those affected by schizophrenia and demonstrate unwavering dedication towards improving outcomes and quality of life for individuals living with this challenging disorder worldwide.

Which are the best cities for schizophrenia clinical trials?

When it comes to schizophrenia clinical trials, several cities emerge as leading hubs for research and development. Atlanta, Georgia boasts 17 active trials focused on investigating treatments like SEP-363856, Xanomeline and Trospium Chloride Capsules, and Infliximab. New york City follows closely behind with 12 ongoing studies exploring interventions such as Clozapine, Brain Basics, and Motivation Skills Training (MST). San Diego, California also stands out with 10 active trials examining potential advancements like SEP-363856 and Xanomeline and Trospium Chloride Capsules. With their commitment to innovative research efforts in the field of schizophrenia treatment, these cities offer hope for improved outcomes for individuals living with this condition.

Which are the top treatments for schizophrenia being explored in clinical trials?

The field of schizophrenia research is rapidly advancing, with several promising treatments being explored in clinical trials. Leading the way is SEP-363856, currently involved in five active trials and boasting a total of 17 all-time studies dedicated to schizophrenia since its listing in 2013. Another noteworthy contender is valbenazine, which has shown promise in three ongoing trials and was first listed just this year (2021). Additionally, transcranial direct current stimulation and cognitive enhancement therapy are both being investigated through multiple active trials, offering new avenues for potential treatment options. Lastly, OLZ/SAM shows potential with two active trials despite its recent introduction in 2021. These exciting developments hold the promise of improved outcomes for individuals living with schizophrenia.

What are the most recent clinical trials for schizophrenia?

Exciting advancements are underway in the field of schizophrenia treatment, as recent clinical trials offer promising possibilities for patients. One such trial investigates the effectiveness of infliximab in managing symptoms and improving overall well-being among individuals with schizophrenia. Another study explores a combination therapy consisting of dasatinib and quercetin, aiming to target specific molecular pathways implicated in the disorder. Additionally, MK-8189 is being evaluated for its potential therapeutic benefits in treating schizophrenia, while SEP-363856 holds promise as a novel compound that may provide relief from psychotic symptoms. Lastly, valbenazine is currently undergoing phase 4 trials to assess its efficacy and safety profile for use in managing schizophrenia symptoms. These exciting developments bring hope and new avenues for those affected by this complex condition.

What schizophrenia clinical trials were recently completed?

Several recent clinical trials have made significant strides in the field of schizophrenia treatment. In July 2022, Merck Sharp & Dohme LLC successfully completed a trial evaluating the potential of MK-8189 for this complex mental disorder. Earlier, in April 2022, another breakthrough was achieved with the completion of a trial testing Nicotine patch as a therapeutic option, sponsored by Merck Sharp & Dohme Corp. Furthermore, Cerevel Therapeutics LLC concluded their CVL-231 study in January 2022 and also finished a separate trial involving CVL-231 Target Release (Fasted) in December 2021. These advances highlight ongoing efforts to address the challenges faced by individuals living with schizophrenia and offer hope for improved treatment options.